Drug intelligence / Profile preview

H0008

Development stage: Preclinical
Lead developer: BioArdis
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

H0008 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy currently under development by BioArdis for the treatment of solid tumors. The program utilizes T-cells engineered to target a proprietary antigen specifically associated with the tumor microenvironment (TME). This approach is intended to enhance the efficacy of cell therapy in solid malignancies by addressing the immunosuppressive nature of the TME and improving T-cell infiltration. As of 2024, H0008 is in the research and preclinical stage of development.

Beyond the preview

Go deeper on H0008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H0008.

Explore the full profile